User:Reixus/sandbox
Reixus [Talk] [Contribs] [Email]
Current Matters
[edit]However, two second generation antipsychotics (clozapine and asenapine), have demonstrated improvements for both the positive and negative symptoms of schizophrenia.[1][2] A few SGAs have also demonstrated to yield cognitive improvements, such as improvements in verbal learning and memory, processing speed, and selective attention.[3] Adjunctive antidepressant use with an atypical antipsychotic has also been demonstrated to be effective for improving the negative symptoms of schizophrenia, such as anhedonia, cognitive deficits, affective flattening, and avolition.[4]
Saved References
[edit]1: Schizophrenia negative symptom improvement from atypical antipsychotics.[5] 2: Adjunctive antidepressant use have demonstrated to improve the negative symptoms of schizophrenia.[4][6] 3: Clozapine for positive and negative symptoms.[1][7][8] 4: Negative symptom treatment with antipsychotics.
References
[edit]- ^ a b Siskind, D; McCartney, L; Goldschlager, R; Kisely, S (7 July 2016). "Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis". The British journal of psychiatry : the journal of mental science. 209: 385–392. doi:10.1192/bjp.bp.115.177261. PMID 27388573.
- ^ Bishara, Delia; Taylor, David (October 12, 2009). "Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder". Neuropsychiatric Disease and Treatment (5): 483–490. PMC 2762364.
{{cite journal}}:|access-date=requires|url=(help) - ^ Wang, Juan; Maorong, Hu; Xiaofeng, Guo; Rengrong, Wu; Lehua, Li; Jingping, Zhao (January 25, 2013). "Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients". Neural Regeneration Research. 8 (3): 277–286. doi:10.3969/j.issn.1673-5374.2013.03.011. PMC 4107525. Retrieved March 23, 2018.
{{cite journal}}: CS1 maint: PMC format (link) - ^ a b Barnes, Thomas RE; Leeson, Verity C; Paton, Carol (April 2016). "Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial". Health Technology Assessment. No. 20.29. Retrieved March 21, 2018.
{{cite journal}}:|volume=has extra text (help) Cite error: The named reference "Antidepressants for NS" was defined multiple times with different content (see the help page). - ^ Fusar-Poli, Paolo; Papanastasiou, Evangelos; Stahl, Daniel; Rocchetti, Matteo; Carpenter, William; Sukhwinder, Shergill; McGuire, Philip (July 1, 2015). "Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials". Schizophrenia Bulletin. 41 (4): 892–899. doi:10.1093/schbul/sbu170. PMC 4466178. Retrieved March 18, 2018.
{{cite journal}}: CS1 maint: PMC format (link) - ^ Mao, Ye-Meng; Zhang, Ming-Dao (March 16, 2015). "Augmentation with antidepressants in schizophrenia treatment: benefit or risk". Neuropsychiatric Disease and Treatment. 11: 701–713. doi:10.2147/NDT.S62266. PMC 4370910. Retrieved March 18, 2018.
{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link) - ^ Bender, S; Dittmann-Balcar, A; Schall, U; Wolstein, J; Klimke, A; Riedel, M (April 2006). "Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine". International Journal of Neuropsychopharmacology. 9 (2): 135–145. doi:10.1017/S1461145705005924. PMID 16174427.
- ^ Potkin, SG; Fleming, K; Gulasekaram, B (October 2001). "Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics". Journal of Clinical Psychopharmacology. PMID 11593072. Retrieved March 4, 2018.